Archive
All News
Every briefing, headline, and filing we've published, newest first.
PolicyKFF Health News ↗
This fact sheet explores the history, funding, and future outlook of the President’s Emergency Plan for AIDS R…
DealsPharmaceutical Technology ↗
The tender offer is for €51.29 per share, representing a 13% premium on Recordati’s share price before the tak…
PipelineFierceBiotech ↗
As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the trip…
DealsFiercePharma ↗
BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthrop…
DealsBriefing
The Engage acquisition marks another move in Lilly’s ongoing deal blitz, targeting preclinical DNA delivery in…
DealsPharmaceutical Technology ↗
Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction …
PolicySTAT News ↗
How a pharma company is soliciting research that can be used to blunt pharma proposed reforms in Washington.…
PipelineSTAT News ↗
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of t…
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
PolicyKFF Health News ↗
This analysis explores recent actions the Trump administration has taken to limit youth access to gender-affir…
PolicyKFF Health News ↗
This brief explains current Medicaid cost sharing rules and changes made to cost sharing rules by the 2025 rec…
PolicyPharmaVoice ↗
The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug i…
DealsFierceBiotech ↗
London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating …
PolicyFiercePharma ↗
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ord…
PipelineBriefing
The global phase 3 win gives Merck’s sacituzumab tirumotecan fresh momentum across 17 ongoing ADC trials, offe…
PipelinePharmaceutical Technology ↗
48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.…
PolicyKFF Health News ↗
This tracker examines Executive Actions taken by the Trump administration that have the potential to impact LG…
PipelineSTAT News ↗
A UCSF team has submitted an application to the FDA seeking approval for a small trial of in utero gene therap…
PolicyEndpoints News ↗
Last week at our biopharma and healthcare summit with the Financial Times, I was asked during one of our break…
DealsFierceBiotech ↗
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now t…
PipelineFiercePharma ↗
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone syntha…
DealsBriefing
After a failed A-T trial and cash crunch, Quince merges with Orphai Therapeutics, keeping its Nasdaq listing a…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.